Phase II randomized placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+ HER2− breast cancer that had progressed during or after prior endocrine therapy

摘要

BackgroundOverexpression of fibroblast growth factor receptor 1 (FGFR1), found in ≤8% of hormone receptor–positive (HR⁺), human epidermal growth factor receptor 2–negative (HER2⁻) breast cancer cases, is correlated with decreased overall survival and resistance to endocrine therapy (ET). Dovitinib, a potent FGFR inhibitor, has demonstrated antitumor activity in heavily pretreated patients with FGFR pathway–amplified breast cancer.